Patient and Parent Perspectives on the Use of Nusinersen for Spinal Muscular Atrophy
At the end of 2016, the U.S. Food and Drug Administration (FDA) approved nusinersen for the treatment of spinal muscular atrophy (SMA).1 Because of the high threshold for FDA approval, an abundance of data on nusinersen and its physiological effects on SMA patients...
How to Administer Nusinersen in Adolescents
Nusinersen is the first treatment available for children with spinal muscular atrophy (SMA). Before its approval in 2016, the U.S. Food and Drug Administration had not approved the use of any drug for SMA treatment.1 While the introduction of this new drug marks...
Administering Nusinersen
Nusinersen (Spinraza) is the first FDA-approved antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in adults and children.1,2 The oligonucleotide is administered intrathecally2; thus, administration is not as straightforward as an...
Chest Physiotherapy and Pulmonary Care in the Acutely Ill Child
Children with spinal muscular atrophy (SMA) often have difficulty with breathing and maintaining blood oxygenation in periods of relative wellness. As such, they often have limited reserve pulmonary and cardiovascular function. Thus during an acute illness, especially...HCP — SMA News Today
BioNews Services, LLC
1601 Market St.
Suite 20B103
Philadelphia, PA 19103
Email: [email protected]
Phone: 1-800-936-1363